Skip to content
Triangle logo TriangleGet started
← Study library

NCT01808534 · REGISTRY CONDITION SEARCH

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2015-07-02

This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate (Defined as Partial Response or Complete Response)

→

outcome · POSTED

Duration of Remission in Patients Who Achieve a Partial or Complete Response

→

outcome · POSTED

Progression Free Survival (PFS)

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Treatment Related Adverse Events Grade 3 or Higher

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histological or serological proof of metastatic germ cell neoplasm (gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy; patients with seminoma and nonseminoma are eligible, as are women with ovarian germ cell tumors * Patients must have evidence of recurrent or metastatic carcinoma by one or more of the criteria specified in the protocol * Patients must have received initial cisplatin based combination therapy (such as bleomycin, etoposide and cisplatin \[BEP\], etoposide and cisplatin \[EP\], VP-16 plus ifosfamide plus cisplatin \[VIP\] or similar regimens) AND demonstrated progression following the administration of at least one 'salvage' regimen for advanced germ cell neoplasm (such as high dose chemotherapy, paclitaxel/ifosfamide/cisplatin \[TIP\] or vinblastine, ifosfamide and cisplatin \[VeIP\]) * Patients must have documented "failure" of prior therapy as defined in the protocol * Patients are eligible after first line platinum based chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor (PMNSGCT) or late relapse (\> 2 years) not amenable to surgical resection * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Laboratory test results must be within ranges established in the protocol * Potential subject must have the ability to understand (as judged by the treating physician) and willingness to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information; * Females of childbearing potential must not be pregnant or breast-feeding; male and female patients of reproductive potential must agree to use a highly reliable method of birth control from the screening visit through 28 days after the last dose of study drug Exclusion Criteria: * No active clinically serious infections as judged by the treating investigator (\> CTCAE grade 2) including known human immunodeficiency virus (HIV) infection or chronic active hepatitis B or active hepatitis C * No presence of, or history of any illness or injury to the urinary tract which may make the patient more susceptible to acute renal insufficiency in the case of potential renal adverse events * Patients must not have any cardiac disorders as defined in the protocol * No history of psychiatric illness/social situations that would limit compliance with study requirements * Patients must be at least 4 weeks post major surgery or significant traumatic injury at time of study registration * Patients must be at least 7 days post any minor surgical procedure, excluding placement of a vascular access device at the time of study registration * Patients must not have a known sensitivity to any component of palifosfamide or its known excipients * Patients with active central nervous system (CNS) metastases are excluded * Patients must not have previously been exposed to palifosfamide * Patients must have at least 3 weeks after previous radiotherapy or chemotherapy and have recovered from all major toxicities (except alopecia or grade 1 or 2 neuropathy) at the time of registration
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Drug: palifosfamide
    label
    Treatment (palifosfamide)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (palifosfamide)
    description
    Given IV
    name
    palifosfamide
    other Names
    1. IPM-lysine
    2. isophosphoramide mustard-lysine
    3. ZIO-201
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
5
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The percent of patients who were shown as having a partial remission or better based on definitions of response in RECIST 1.1. At least a 30% decrease in the sum of the diameters of target lesions, in reference to baseline sum diameters, needs to be confirmed to be considered as partial response or better. Note: There were no patients with a partial or complete response.
    measure
    Overall Response Rate (Defined as Partial Response or Complete Response)
    time Frame
    Up to 2 years
secondary Outcomes
  1. description
    The duration of remission is from the time of confirmed partial or complete response until progression or death. Patients continuing in remission at the end of the study will be treated as censored. Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley. Note: There were no patients who achieved partial or complete response.
    measure
    Duration of Remission in Patients Who Achieve a Partial or Complete Response
    time Frame
    Up to 2 years
  2. description
    Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley. Time until progression, death or last evaluation will be calculated. If a patient did not progress or die, they will be censored at their last evaluation in the analysis.
    measure
    Progression Free Survival (PFS)
    time Frame
    Up to 2 years
  3. description
    Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley. Time until death or last evaluation will be calculated. If a patient did not die, they will be censored in the analysis at their last known alive date.
    measure
    Overall Survival
    time Frame
    Up to 2 years
  4. description
    Number of unique patients who had a treatment related (possible, probable or definite) adverse event that was graded 3 or greater according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
    measure
    Treatment Related Adverse Events Grade 3 or Higher
    time Frame
    Up to 2 years
Full study description
brief Summary
This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
detailed Description
PRIMARY OBJECTIVES: I. To determine the response rate (complete response \[CR\]+partial response \[PR\]) of single agent palifosfamide in patients with refractory germ cell tumors. SECONDARY OBJECTIVES: I. To determine the duration of remission. II. To determine progression free and overall survival. III. To assess toxicity and tolerability of palifosfamide in patients with germ cell tumors. OUTLINE: Patients receive palifosfamide intravenously (IV) over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a9996f235afa020e60e3
      requested nct id
      NCT01808534
      primary nct id
      NCT01808534
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      payload sha256
      67b0048395ca9c33bf1233cf77d08a284e91792b74476ae33a773fe88290f6a8
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a9996f235afa020e60e3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01808534
      occurrences
      1. context exact
        NCT01808534
        end
        11
        exact text
        NCT01808534
        start
        0
      offset unit
      unicode_code_points
      query cond
      Ovarian Germ Cell Tumors
      query disease state id
      ds-ovarian-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      source json pointer
      /studies/51/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6bb0e818d0f3555a69293858a1be391bf73297d33ff8f98e3236bc5fb4a625bd
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d5740590e0178e5a9c6f
      requested nct id
      NCT01808534
      primary nct id
      NCT01808534
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a10e8ef1fa9256ee3fc97c8f1232aa3fc01529e26a627718afd38186807a7f67
      payload sha256
      22a2cf31ff40f6a181806e4e0a4518fcf968e4d93156aa1843539c135a92aa23
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d5740590e0178e5a9c6f
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01808534
      occurrences
      1. context exact
        NCT01808534
        end
        11
        exact text
        NCT01808534
        start
        0
      offset unit
      unicode_code_points
      query cond
      Extragonadal Germ Cell Tumors
      query disease state id
      ds-extragonadal-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-extragonadal-germ-cell-tumors-000.json
      source file sha256
      a10e8ef1fa9256ee3fc97c8f1232aa3fc01529e26a627718afd38186807a7f67
      source json pointer
      /studies/8/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6bb0e818d0f3555a69293858a1be391bf73297d33ff8f98e3236bc5fb4a625bd
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e91b4e79b13483f14577
      requested nct id
      NCT01808534
      primary nct id
      NCT01808534
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      payload sha256
      a04fe6e509e715dfeec3095f071a6b705fa9295b8438b549db696d0636b12ddd
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e91b4e79b13483f14577
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01808534
      occurrences
      1. context exact
        NCT01808534
        end
        11
        exact text
        NCT01808534
        start
        0
      offset unit
      unicode_code_points
      query cond
      Testicular Cancer
      query disease state id
      ds-testicular-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      source json pointer
      /studies/32/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6bb0e818d0f3555a69293858a1be391bf73297d33ff8f98e3236bc5fb4a625bd

    Preserved source evidence · Not medical advice